UPDATE 1-Pfizer's Ibrance drug slows progression of breast cancer

CHICAGO May 30 (Reuters) - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the...